Novo Nordisk's oral semaglutide (Wegovy) became the first oral GLP-1 approved for weight loss and CV risk reduction, with commercial rollout in early 2026 after FDA approval in late 2025.145
The GLP-1 pill launched successfully, gaining 246,000 users in five weeks as of February 2026.5
Pipeline highlights include semaglutide 25 mg oral Ozempic (FDA decision 4Q 2026), semaglutide 7.2 mg Wegovy SC (1Q 2026), CagriSema (cagrilintide + semaglutide, FDA decision December 2026), and Amycretin oral dual agonist showing 13% weight loss.1346
Analysts express caution on CagriSema's weight loss efficacy despite FDA submission, while oral drugs like Eli Lilly's orforglipron (expected 2Q 2026) intensify competition.146
Novo Nordisk pursues pipeline diversification with triple agonists (GLP-1/GIP/amylin and GLP-1/GIP/glucagon) and explores addiction indications for GLP-1s.6
Sources:
1. https://www.primetherapeutics.com/glp-1-pipeline-update-february-2026
3. https://www.novonordisk.com/science-and-technology/r-d-pipeline.html
4. https://www.iqvia.com/locations/emea/blogs/2026/01/outlook-for-obesity-in-2026
5. https://www.youtube.com/watch?v=cLVrYnFkQAQ
6. https://www.fiercebiotech.com/biotech/laden-glp-1-cash-novo-nordisk-craves-different-flavors-pipeline-innovation-exec-says